These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23002203)

  • 81. Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
    Liu X; Kung A; Malinoski B; Prakash GK; Zhang C
    J Med Chem; 2015 Dec; 58(23):9228-37. PubMed ID: 26562217
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
    Kakarala KK; Jamil K
    J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
    [TBL] [Abstract][Full Text] [Related]  

  • 87. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
    Han HJ; Kim JJ; Pyne D; Travas A; Ambalavanan A; Kimura S; Deininger MW; Kim JW; Kim DDH
    Leukemia; 2024 Feb; 38(2):412-415. PubMed ID: 38155246
    [No Abstract]   [Full Text] [Related]  

  • 88. Structure, regulation, signaling, and targeting of abl kinases in cancer.
    Hantschel O
    Genes Cancer; 2012 May; 3(5-6):436-46. PubMed ID: 23226581
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Principles of Kinase Allosteric Inhibition and Pocket Validation.
    Pan Y; Mader MM
    J Med Chem; 2022 Apr; 65(7):5288-5299. PubMed ID: 35312319
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
    Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
    Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.
    Lemeer S; Zörgiebel C; Ruprecht B; Kohl K; Kuster B
    J Proteome Res; 2013 Apr; 12(4):1723-31. PubMed ID: 23495751
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.
    Nussinov R; Zhang M; Maloney R; Liu Y; Tsai CJ; Jang H
    J Mol Biol; 2022 Sep; 434(17):167569. PubMed ID: 35378118
    [TBL] [Abstract][Full Text] [Related]  

  • 93. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.
    Littlefield P; Moasser MM; Jura N
    Chem Biol; 2014 Apr; 21(4):453-458. PubMed ID: 24656791
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of a novel target site for ATP-independent ERK2 inhibitors.
    Yoshida M; Nagao H; Sugiyama H; Sawa M; Kinoshita T
    Biochem Biophys Res Commun; 2022 Feb; 593():73-78. PubMed ID: 35063772
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reply to Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
    Johnson TK; Bochar DA; Vandecan NM; Furtado J; Agius MP; Phadke S; Soellner MB
    Angew Chem Int Ed Engl; 2022 Nov; 61(46):e202209518. PubMed ID: 36283971
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
    Boffey HK; Rooney TPC; Willems HMG; Edwards S; Green C; Howard T; Ogg D; Romero T; Scott DE; Winpenny D; Duce J; Skidmore J; Clarke JH; Andrews SP
    J Med Chem; 2022 Feb; 65(4):3359-3370. PubMed ID: 35148092
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Structure prediction and validation of the ERK8 kinase domain.
    Strambi A; Mori M; Rossi M; Colecchia D; Manetti F; Carlomagno F; Botta M; Chiariello M
    PLoS One; 2013; 8(1):e52011. PubMed ID: 23326322
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
    Cowan-Jacob SW; Jahnke W; Knapp S
    Future Med Chem; 2014 Apr; 6(5):541-61. PubMed ID: 24649957
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket.
    Grzesiek S; Paladini J; Habazettl J; Sonti R
    Magn Reson (Gott); 2022; 3(1):91-99. PubMed ID: 37905178
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".
    Hantschel O; Grebien F; Superti-Furga G
    Oncotarget; 2011 Nov; 2(11):828-9. PubMed ID: 22084171
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.